RCKT vs. JANX, RCUS, SNDX, ARDX, STOK, XERS, ZYME, AMLX, SION, and TLRY
Should you be buying Rocket Pharmaceuticals stock or one of its competitors? The main competitors of Rocket Pharmaceuticals include Janux Therapeutics (JANX), Arcus Biosciences (RCUS), Syndax Pharmaceuticals (SNDX), Ardelyx (ARDX), Stoke Therapeutics (STOK), Xeris Biopharma (XERS), Zymeworks (ZYME), Amylyx Pharmaceuticals (AMLX), Sionna Therapeutics (SION), and Tilray Brands (TLRY). These companies are all part of the "pharmaceutical products" industry.
Rocket Pharmaceuticals vs. Its Competitors
Rocket Pharmaceuticals (NASDAQ:RCKT) and Janux Therapeutics (NASDAQ:JANX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.
Rocket Pharmaceuticals presently has a consensus price target of $16.67, indicating a potential upside of 401.25%. Janux Therapeutics has a consensus price target of $78.31, indicating a potential upside of 227.44%. Given Rocket Pharmaceuticals' higher probable upside, analysts clearly believe Rocket Pharmaceuticals is more favorable than Janux Therapeutics.
Janux Therapeutics has higher revenue and earnings than Rocket Pharmaceuticals. Janux Therapeutics is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Rocket Pharmaceuticals had 6 more articles in the media than Janux Therapeutics. MarketBeat recorded 7 mentions for Rocket Pharmaceuticals and 1 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 0.00 beat Rocket Pharmaceuticals' score of -0.21 indicating that Janux Therapeutics is being referred to more favorably in the news media.
98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are owned by institutional investors. 24.8% of Rocket Pharmaceuticals shares are owned by company insiders. Comparatively, 29.4% of Janux Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Janux Therapeutics' return on equity of -11.48% beat Rocket Pharmaceuticals' return on equity.
Rocket Pharmaceuticals has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Comparatively, Janux Therapeutics has a beta of 2.82, suggesting that its stock price is 182% more volatile than the S&P 500.
Summary
Janux Therapeutics beats Rocket Pharmaceuticals on 11 of the 15 factors compared between the two stocks.
Get Rocket Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RCKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rocket Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:RCKT) was last updated on 10/8/2025 by MarketBeat.com Staff
